Jump to main content

The New York Times and ProPublica 07/12/2017

Is Outcomes-Based Contracting Worth It?

Katie Thomas and Charles Ornstein examine the costs and benefits of outcomes-based contracting.

Following an op-ed by Anna Kaltenboeck and Dr. Peter Bach in Morning Consult, the New York Times and ProPublica take a closer look at the potential costs and benefits of outcomes-based contracting.

Read the full article here.

"Dr. Bach and others say the pharmaceutical industry is using this approach to justify major changes in federal regulations [...] The industry says the changes are needed to allow more flexibility in the type of deals they offer."

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Explore Our Research

Academic Literature

Value-Based Pricing for Drugs: Theme and Variations

A taxonomy of the features that make a payment model truly value-based.

JAMA Viewpoint 05/02/2018

Outcomes-Based Drug Contracts Do Not Move Us Closer to Value

What steps are needed to make outcomes-based contracting a value-based approach?

Morning Consult 06/21/2017

Xeljanz, the FDA, and nine years of patient harm

Quantifying population-level adverse events in the near decade between when safety concerns were identified and FDA action

Drug Pricing Lab 05/31/2022

Atypical antipsychotics: Decades of use, unfathomable harms

Using attributable risk calculations to quantify how many premature deaths resulted from atypical antipsychotic use in the elderly

Drug Pricing Lab 05/31/2022

Medicare Part B Premium Dynamics Explained

The Drug Pricing Lab commissioned Milliman to prepare a report exploring the impact of changes in Medicare Part B program costs on beneficiaries’ premiums and Social Security payments. This report focuses on the 2022 Part B premium for beneficiaries with various income levels to illustrate the payment dynamics and discusses the implications for related programs.

Milliman 12/23/2021

Comparing Factors that Influence Pharmaceutical Pricing and Access in the…

Drug prices in the United States are some of the highest in the world, which has triggered several policy proposals aimed at adopting pricing strategies used by other countries.

Drug Pricing Lab 12/20/2021

Biosimilars in Medicare Part D: pricing dynamics and considerations

The Drug Pricing Lab engaged Milliman to prepare a report summarizing the pricing dynamics affecting utilization of biosimilars in the current Medicare Part D marketplace and under the proposed Part D benefit design in the Build Back Better Act.

This report was commissioned by the Drug Pricing Lab.

Milliman 12/14/2021

Evaluating Industry’s Drug Pricing Claims

A closer look at three of PhRMA’s most cited talking points.

Drug Pricing Lab 11/18/2021

Mapping conflict of interests: scoping review

A scoping review of the literature to identify all known ties between the medical product industry and the parties and activities in the healthcare ecosystem.

Drug Pricing Lab 11/03/2021

Production Plus Profit Pricing (P-quad) FAQ

Academic Literature

What A Waste! The National Academy Of Medicine’s Report On…

Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.

Health Affairs Blog 07/09/2021

Medicare Must Study Unproven, Expensive Alzheimer’s Drug

Medicare cannot indiscriminately cover the cost of Aduhelm for the treatment of Alzheimer's disease without first evaluating whether it truly works.

Bloomberg Opinion 06/15/2021

Explore Our Research